Compare CDW Corp. (CDW) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CDW Corp. vs Nuwellis Inc — how do they compare? CDW Corp. trades at $144.5 (market cap $17.81B), while Nuwellis Inc trades at $3.32 (market cap $1.17M). The key difference: CDW Corp. is far larger — about 15222.2× Nuwellis Inc's market cap, and CDW Corp. pays a 1.81% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| CDW | NUWE | |
|---|---|---|
Market Cap | $17.81B | $1.17M |
Sector | Technology | Technology |
52-Week High | $182.18 | $558.26 |
52-Week Low | $99.30 | $2.80 |
Enterprise Value | $23.02B | -$636.97K |
Dividend Yield | 1.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CDW trades at $144.36, down slightly by 0.02% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $145.83. The company reported Q1 2026 earnings that met expectations with $2.28 EPS, following beats in previous quarters. Revenue for 2025 was $22.42B with a net income margin of 4.7%, while valuation metrics show a P/E of 17.58 and P/S of 0.83. Recent news highlights AI infrastructure demand and a $1B share repurchase authorization.
The outlook for CDW is positive, driven by AI growth opportunities and strong profitability, but risks include margin pressure and competitive threats. Analysts are bullish with 70.59% buy ratings, suggesting potential upside from current levels, though investors should monitor execution on earnings targets and macroeconomic conditions.
NUWE trades at $2.80, down 7.89% in the last session, with a bearish technical outlook from moving averages. The company reported a net loss of $17.52 million in 2025 despite $8.27 million revenue, reflecting a negative net margin of 217.22%. Recent developments include a CEO transition to Mike McCormick, a $6 million public offering in June 2026, and expansion in pediatric care installations, indicating strategic growth efforts amid financial challenges.
The outlook remains high-risk due to persistent losses and negative ROE/ROA, though low P/E and P/B ratios suggest undervaluation. Analyst sentiment is split evenly between buy and hold. Key risks include cash burn from negative operating cash flow and execution hurdles in scaling commercial adoption. Upside depends on revenue acceleration and cost management under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
